Recent advances in second-line treatment of castration-resistant prostate cancer

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 3, 2011, Pages 199-205

  Ong, Michael ^a   Winquist, Eric ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Abiraterone; Cabazitaxel; Castration resistant prostate cancer; Review; Treatment

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

HUMAN; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; TIME; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TIME FACTORS; TREATMENT FAILURE;

EID: 80052758032     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32834903aa     Document Type: Review

References (39)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907.
2. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-1159.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
4. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. (Pubitemid 39315318)
5. Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008; 2:161-166.
6. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154. This trial was the first to show a survival advantage of a second-line chemotherapy after the failure of first-line docetaxel in metastatic CRPC. Cabazitaxel is a novel taxane chemotherapy that is structurally similar to docetaxel.
7. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364:1995-2005. This is a large randomized clinical trial showing that abiraterone acetate improves overall survival of patients in docetaxel-refractory castration-resistant prostate cancer, with tolerable side-effects related to mineralocorticoid excess.
8. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-5438.
9. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-245.
10. Di Lorenzo G, Buonerba C, Faiella A, et al. Phase II study of docetaxel retreatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011; 107:234-239. This nonrandomized phase II trial is one of the few prospective trials published examining rechallenge of docetaxel 75 mg/m2 intravenous for 3 weeks.
11. Eymard JC, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106:974-978.
12. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764. (Pubitemid 26185452)
13. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506- 2513. (Pubitemid 29368252)
14. Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168:2439- 2443. (Pubitemid 35402635)
15. Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of Oncology 2008; 19:1749-1753.
16. Cisternino S, Bourasset F, Archimbaud Y, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003; 138:1367- 1375. (Pubitemid 36543135)
17. NHS Regional Drug & Therapeutics Centre Evaluation Report February 2011. The use of cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer. http://www.nyrdtc.nhs.uk/docs/eva/RDTC-Cabazitaxel-ER.pdf [Accessed July 2011].
18. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-1552.
19. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily (X)5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005; 23:79-84. (Pubitemid 39505954)
20. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175:27-34. (Pubitemid 41797079)
21. Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112:2393-2400.
22. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164:217- 227. (Pubitemid 38364606)
23. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825.
24. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med 2009; 133:1033-1040.
25. Navarro D, Luzardo OP, Fernandez L, et al. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002; 81:191- 201. (Pubitemid 34879930)
26. Ganong WF. Review of Medical Physiology, McGraw-Hill; 2001, 20th edition, 350 pp.
27. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alphahydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90:2317-2325. (Pubitemid 38961894)
28. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
29. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castrationresistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-1488. This prospective phase I trial has an interesting analysis of changes in levels of steroids along the adrenal steroid biosynthetic pathway after inhibition with abiraterone acetate.
30. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
31. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45. (Pubitemid 33741879)
32. Cochrane DR, Wang Z, Muramaki M, et al. Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem 2007; 282:2278-2287. (Pubitemid 47076744)
33. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50:179-188. (Pubitemid 34137445)
34. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16:1088-1093.
35. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study ofOGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287-1296. (Pubitemid 41535369)
36. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 20-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14:833-839. (Pubitemid 351231167)
37. Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102:389-397. (Pubitemid 352019195)
38. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103:1636-1640.
39. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21:319-324.